Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review
Abstract Background As a modulator of the sphingosine 1-phosphate receptor, siponimod is administered as a therapeutic intervention for multiple sclerosis. A previous phase 3 study first reported siponimod-associated macular edema. Since that report, there were only few relevant reports in clinical...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-023-03333-0 |
| _version_ | 1827875441185128448 |
|---|---|
| author | Qingsheng Li Li-Jun Jing Yanfei Li Yanjie Jia |
| author_facet | Qingsheng Li Li-Jun Jing Yanfei Li Yanjie Jia |
| author_sort | Qingsheng Li |
| collection | DOAJ |
| description | Abstract Background As a modulator of the sphingosine 1-phosphate receptor, siponimod is administered as a therapeutic intervention for multiple sclerosis. A previous phase 3 study first reported siponimod-associated macular edema. Since that report, there were only few relevant reports in clinical settings. Here, we report a case of secondary progressive multiple sclerosis developed macular edema after siponimod treatment. We also review the progress of sphingosine 1-phosphate receptor modulators, elaborate on accepted mechanisms in treating multiple sclerosis, and discuss the causation of siponimod-associated macular edema. Case presentation A 38-year-old Chinese female patient with secondary progressive multiple sclerosis, who had recurrent numbness of the limbs and right leg fatigue, developed mild macular edema following 4 months of siponimod treatment. The macular edema resolved after discontinuing the medication, and did not recur after resuming siponimod. Conclusion Although siponimod-associated macular edema may be rare, mild, transitory, and manageable, it cannot be ignored and requires ongoing vigilance. |
| first_indexed | 2024-03-12T17:06:52Z |
| format | Article |
| id | doaj.art-2eff69f0e159424fbecf6e6a013c494d |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-03-12T17:06:52Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-2eff69f0e159424fbecf6e6a013c494d2023-08-06T11:18:14ZengBMCBMC Neurology1471-23772023-07-012311610.1186/s12883-023-03333-0Macular edema after siponimod treatment for multiple sclerosis: a case report and literature reviewQingsheng Li0Li-Jun Jing1Yanfei Li2Yanjie Jia3Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou UniversityDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou UniversityDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou UniversityDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou UniversityAbstract Background As a modulator of the sphingosine 1-phosphate receptor, siponimod is administered as a therapeutic intervention for multiple sclerosis. A previous phase 3 study first reported siponimod-associated macular edema. Since that report, there were only few relevant reports in clinical settings. Here, we report a case of secondary progressive multiple sclerosis developed macular edema after siponimod treatment. We also review the progress of sphingosine 1-phosphate receptor modulators, elaborate on accepted mechanisms in treating multiple sclerosis, and discuss the causation of siponimod-associated macular edema. Case presentation A 38-year-old Chinese female patient with secondary progressive multiple sclerosis, who had recurrent numbness of the limbs and right leg fatigue, developed mild macular edema following 4 months of siponimod treatment. The macular edema resolved after discontinuing the medication, and did not recur after resuming siponimod. Conclusion Although siponimod-associated macular edema may be rare, mild, transitory, and manageable, it cannot be ignored and requires ongoing vigilance.https://doi.org/10.1186/s12883-023-03333-0Multiple sclerosisSiponimodSphingosine 1-phosphateMacular edemaCase report |
| spellingShingle | Qingsheng Li Li-Jun Jing Yanfei Li Yanjie Jia Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review BMC Neurology Multiple sclerosis Siponimod Sphingosine 1-phosphate Macular edema Case report |
| title | Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review |
| title_full | Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review |
| title_fullStr | Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review |
| title_full_unstemmed | Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review |
| title_short | Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review |
| title_sort | macular edema after siponimod treatment for multiple sclerosis a case report and literature review |
| topic | Multiple sclerosis Siponimod Sphingosine 1-phosphate Macular edema Case report |
| url | https://doi.org/10.1186/s12883-023-03333-0 |
| work_keys_str_mv | AT qingshengli macularedemaaftersiponimodtreatmentformultiplesclerosisacasereportandliteraturereview AT lijunjing macularedemaaftersiponimodtreatmentformultiplesclerosisacasereportandliteraturereview AT yanfeili macularedemaaftersiponimodtreatmentformultiplesclerosisacasereportandliteraturereview AT yanjiejia macularedemaaftersiponimodtreatmentformultiplesclerosisacasereportandliteraturereview |